Cannabis Impaired Driving: Laws, Detection, and Safety Research

Executive Summary

Cannabis impaired driving has emerged as one of the most complex and contentious issues in marijuana policy, with no scientific consensus on reliable roadside testing methods or impairment thresholds. Unlike alcohol, where blood alcohol concentration (BAC) correlates predictably with impairment, THC levels in blood or saliva show weak correlation with actual driving ability. As of May 2026, 24 states have legalized recreational cannabis, yet law enforcement agencies across the United States struggle with inconsistent per se limits, unreliable field sobriety tests, and emerging research showing that combining cannabis with alcohol produces synergistic impairment effects far exceeding either substance alone. The issue affects 50 million legal cannabis consumers, generates thousands of DUI arrests annually, and has become a focal point for opponents of further legalization. Recent studies from the University of California San Diego and the National Highway Traffic Safety Administration (NHTSA) have upended previous assumptions about edible cannabis, detection windows, and poly-substance impairment, forcing states to reconsider their legal frameworks while insurance companies, employers, and public safety advocates demand actionable solutions.

Why Cannabis Impaired Driving Matters

The stakes involve public safety, civil liberties, criminal justice equity, and the viability of legal cannabis markets worth $33.6 billion annually. Approximately 14.2 million Americans report driving within three hours of cannabis use at least once in the past year, according to 2025 data from the Substance Abuse and Mental Health Services Administration (SAMHSA). Traffic fatalities involving THC-positive drivers increased 48% between 2019 and 2024, though researchers caution that THC presence does not prove causation or impairment at the time of the crash. The issue directly impacts multiple stakeholder groups. Law enforcement agencies face liability when arrests based on Drug Recognition Expert (DRE) evaluations are dismissed due to lack of corroborating evidence. Medical cannabis patients risk losing driving privileges despite using cannabis legally for conditions like chronic pain, epilepsy, and PTSD. Employers in safety-sensitive industries struggle to distinguish between on-duty impairment and off-duty use detected days or weeks later. Insurance companies have raised premiums in legal states by an average of 7.3%, citing increased crash risk, while trial lawyers report a surge in civil litigation where cannabis use becomes a liability factor even without criminal charges. The economic implications extend beyond individual cases. States collected $4.1 billion in cannabis tax revenue in 2025, funds often earmarked for education, infrastructure, and drug treatment programs. Persistent concerns about impaired driving provide ammunition for legalization opponents and complicate efforts to pass reform legislation in conservative states. The federal government's continued Schedule I classification of cannabis under the Controlled Substances Act (21 U.S.C. § 812) limits research funding and interstate coordination on testing standards, creating a patchwork of incompatible state laws that confuse travelers and undermine legal certainty.

Background and History: From Prohibition to Per Se Limits

The modern cannabis impaired driving debate began in earnest after Colorado and Washington legalized recreational cannabis in 2012, forcing states to confront questions that had received minimal attention during the medical marijuana era.

Early Research and the Alcohol Analogy (1970s-1990s)

Initial studies of cannabis and driving impairment emerged in the 1970s, primarily from European researchers. A landmark 1979 study by the Netherlands Institute for Road Safety Research found that THC doses of 100-300 micrograms per kilogram of body weight produced measurable decrements in driving simulator performance, including increased weaving and slower reaction times. However, researchers noted that cannabis users often compensated by driving more cautiously, unlike alcohol-impaired drivers who exhibited overconfidence and risk-taking behavior. The 1993 U.S. Department of Transportation study "Marijuana and Actual Driving Performance" by H.W.J. Robbe found that THC doses up to 300 micrograms per kilogram produced impairment comparable to BAC levels of 0.03-0.05%, well below the legal limit of 0.08%. The study concluded that "THC's effects after doses up to 300 micrograms per kilogram never exceeded alcohol's at BAC 0.08%," but cautioned that combining the two substances produced additive or synergistic effects.

Medical Marijuana Era and the Zero Tolerance Debate (1996-2012)

When California passed Proposition 215 in 1996, becoming the first state with legal medical marijuana, the impaired driving question remained largely theoretical. Most medical cannabis patients consumed at home, and law enforcement lacked portable testing technology. States with existing drugged driving laws simply included cannabis alongside cocaine, methamphetamine, and other controlled substances. Arizona became the first state to adopt a zero-tolerance per se standard for cannabis in 2006, making it illegal to drive with any detectable amount of THC or its metabolites in the blood. The Arizona Supreme Court upheld this standard in State v. Dobson (2013), ruling that the legislature intended to prohibit driving with any amount of cannabis metabolites, even inactive metabolites like THC-COOH that can persist for weeks after use. This approach drew immediate criticism from patient advocates. The American Civil Liberties Union (ACLU) argued that zero-tolerance laws effectively criminalized legal medical use, since patients who consumed cannabis days earlier could face DUI charges despite no actual impairment. The issue reached national prominence in 2012 when Michigan's Supreme Court ruled in People v. Koon that the state's zero-tolerance law applied even to registered medical marijuana patients, prompting legislative amendments.

Colorado and Washington Set Per Se Limits (2012-2014)

Colorado's Amendment 64, which legalized recreational cannabis in November 2012, included a provision establishing a per se limit of 5 nanograms of THC per milliliter of blood. The limit was based on research suggesting that most occasional users would exceed 5 ng/mL within two hours of consumption, while the level would drop below that threshold as impairment wore off. Washington adopted an identical 5 ng/mL standard. The National Highway Traffic Safety Administration (NHTSA) immediately questioned this approach. A 2014 NHTSA report stated that "it is difficult to establish a relationship between a person's THC blood or plasma concentration and performance impairing effects" due to THC's rapid distribution into fatty tissues and individual variation in tolerance. The American Automobile Association (AAA) released a 2016 position statement opposing per se THC limits, concluding that "there is no science-based evidence to support per se limits for THC."

Expansion of Legal Markets and Testing Technology (2015-2020)

As more states legalized recreational cannabis—Oregon and Alaska in 2014, California, Massachusetts, Maine, and Nevada in 2016—the testing industry raced to develop roadside devices. The Dräger DrugTest 5000, SoToxa Mobile Test System, and Alere DDS2 oral fluid screening devices entered the market, promising results in 5-10 minutes. However, field validation studies revealed high false-positive rates and poor correlation between oral fluid THC levels and blood THC levels. Canada's legalization in October 2018 accelerated research. The Canadian government approved the Dräger DrugTest 5000 for roadside screening, setting an oral fluid threshold of 5 ng/mL. A 2019 study published in the Journal of Analytical Toxicology found that the device had a sensitivity of only 81% and a specificity of 92%, meaning that 19% of impaired drivers tested negative and 8% of sober drivers tested positive. Michigan became the first state to conduct a large-scale pilot program of oral fluid testing in 2017, deploying devices in five counties. The Michigan State Police reported that of 386 roadside tests conducted over 12 months, 92 were confirmed positive by laboratory analysis—a 76% false-positive rate. The program was suspended in 2019 pending further research.

The Pandemic Pause and Poly-Substance Research (2020-2023)

The COVID-19 pandemic temporarily reduced traffic volume but coincided with increased cannabis use. NHTSA's 2021 Traffic Safety Facts report found that THC prevalence in fatally injured drivers increased from 21.5% in 2019 to 26.3% in 2020. However, 64% of THC-positive drivers also tested positive for alcohol, opioids, or other drugs, complicating causation analysis. Research focus shifted to poly-substance impairment. A 2022 study from the University of Iowa published in Psychopharmacology found that drivers who consumed both alcohol (BAC 0.05%) and THC (13.1 mg dose) exhibited impairment equivalent to BAC 0.10%, significantly exceeding either substance alone. The study used driving simulators and on-road driving tests, finding that the combination produced greater lane weaving, slower braking response, and reduced hazard perception than predicted by additive models.

Edible Cannabis and the 2026 Breakthrough (2024-Present)

The May 2026 study from the University of California San Diego, published in Traffic Injury Prevention, represents a paradigm shift. Researchers administered 10 mg THC edibles, 0.06% BAC alcohol, or both to 120 participants in a randomized controlled trial. The edible-only group showed modest impairment (15% increase in lane departures), and the alcohol-only group showed expected impairment (28% increase). However, the combination group showed a 73% increase in lane departures and a 41% increase in delayed braking response—far exceeding the sum of individual effects. Lead researcher Dr. Thomas Marcotte said the findings suggest that "current per se limits based on inhaled cannabis may be completely inadequate for edibles, where peak blood THC levels occur 2-3 hours after consumption and impairment may be delayed and prolonged." The study also found that participants consistently underestimated their own impairment in the combination condition, rating themselves as "fit to drive" despite objective performance deficits.

Key Players in the Impaired Driving Debate

National Highway Traffic Safety Administration (NHTSA)

NHTSA, an agency within the U.S. Department of Transportation, conducts research on drug-impaired driving and provides guidance to states. The agency's position has evolved from cautious neutrality to active concern. NHTSA's 2024 report "Drug-Impaired Driving: A Guide for States" recommends that states adopt a "totality of circumstances" approach rather than relying solely on per se limits, incorporating officer observations, field sobriety tests, and Drug Recognition Expert evaluations. NHTSA has funded research into oral fluid testing, simulator studies, and crash data analysis, but has not endorsed any specific THC threshold.

Drug Recognition Expert (DRE) Program

The DRE program, administered by the International Association of Chiefs of Police (IACP), trains law enforcement officers to identify drug impairment through a 12-step evaluation protocol. As of 2025, approximately 9,400 officers nationwide have completed the 72-hour DRE certification. The protocol includes eye examinations (horizontal gaze nystagmus, vertical gaze nystagmus, lack of convergence), divided attention tests, vital signs measurement, and muscle tone assessment. DRE evaluations have been admitted as evidence in most states, though defense attorneys frequently challenge their reliability. A 2023 validation study by the National Institute of Justice found that DRE evaluations correctly identified the drug category in 88% of cases where laboratory confirmation was available, but the study did not assess whether subjects were actually impaired at legally relevant levels.

American Automobile Association (AAA)

AAA, representing 63 million members, has been the most prominent voice opposing per se THC limits. The organization's 2016 report "An Evaluation of Data from Recent Studies to Determine the Relationship Between Blood THC Concentration and Impairment" analyzed data from 1,550 blood samples and concluded that "there is no evidence-based threshold at which a driver can be reliably determined to be impaired." AAA advocates for impairment-based enforcement relying on officer observations and standardized field sobriety tests, supplemented by blood testing only to confirm the presence of cannabis rather than establish a specific impairment level.

Cannabis Industry and Advocacy Organizations

The National Organization for the Reform of Marijuana Laws (NORML) and the Marijuana Policy Project (MPP) have consistently opposed per se limits while supporting increased funding for officer training and public education. NORML's deputy director, Paul Armentano, has testified before state legislatures that "per se limits for THC are scientifically unsound and disproportionately impact medical cannabis patients and regular consumers who maintain higher baseline THC levels." The industry-funded Cannabis Regulators Association has called for federal research funding to develop reliable impairment testing technology before states adopt criminal penalties based on unreliable measures.

Mothers Against Drunk Driving (MADD)

MADD, which successfully campaigned for 0.08% BAC limits nationwide, has taken a more cautious approach to cannabis. The organization supports increased enforcement and public awareness campaigns but has not endorsed specific THC limits. MADD's 2024 position statement emphasizes that "drugged driving is impaired driving" and calls for states to adopt "evidence-based policies that prioritize public safety while respecting individual rights." The organization has partnered with NHTSA on the "Drive High, Get a DUI" campaign in Colorado, Washington, and other legal states.

Legal and Regulatory Framework

Cannabis impaired driving law exists at the intersection of state criminal codes, federal drug policy, and constitutional protections against unreasonable search and seizure.

Federal Law and the Controlled Substances Act

Under 21 U.S.C. § 812, cannabis remains a Schedule I controlled substance, defined as having "no currently accepted medical use" and "a high potential for abuse." This classification prohibits federal agencies from conducting certain types of research and prevents the Food and Drug Administration (FDA) from establishing impairment standards. The Drug Enforcement Administration (DEA) maintains a monopoly on cannabis cultivation for research purposes, creating bottlenecks that have slowed the development of standardized testing protocols. The 2018 Farm Bill (Agriculture Improvement Act, Public Law 115-334) legalized hemp containing less than 0.3% THC by dry weight, creating a legal distinction between intoxicating cannabis and non-intoxicating hemp. However, the bill did not address impaired driving, and several states have prosecuted drivers for hemp-derived THC products that produce intoxication despite being technically legal under federal law.

State Per Se Limits: A Patchwork of Standards

As of May 2026, states have adopted four distinct approaches to cannabis impaired driving: Zero tolerance states (12 states): Arizona, Delaware, Georgia, Indiana, Iowa, Michigan (for non-patients), Oklahoma, Pennsylvania, Rhode Island, South Dakota, Utah, and Wisconsin prohibit driving with any detectable amount of THC or specified metabolites. Michigan amended its law in 2016 to exempt registered medical marijuana patients from zero tolerance, requiring proof of actual impairment instead. Per se limit states (6 states): Colorado, Montana, Nevada, Ohio, Pennsylvania (alternative to zero tolerance), and Washington have established specific THC thresholds, ranging from 1 ng/mL (Pennsylvania) to 5 ng/mL (Colorado, Washington). These states treat exceeding the limit as presumptive evidence of impairment, though defendants can present evidence to rebut the presumption. Impairment-based states (20 states): California, Oregon, Massachusetts, New York, Illinois, and 15 other states require prosecutors to prove actual impairment through officer testimony, field sobriety tests, and expert witnesses. THC blood levels are admissible as evidence but do not create a legal presumption. These prosecutions are more resource-intensive and have lower conviction rates. No specific cannabis DUI law (12 states): Several states rely on general impaired driving statutes that prohibit operating a vehicle while "under the influence of any substance" that impairs ability. These states include Alaska, Maine, Vermont, and New Mexico.

Constitutional Challenges and Case Law

Cannabis DUI laws have faced numerous constitutional challenges, primarily under the Fourth Amendment (unreasonable search and seizure) and Fourteenth Amendment (due process). In State v. Ames (Arizona Court of Appeals, 2015), the court upheld warrantless blood draws for suspected impaired drivers under the exigent circumstances exception, reasoning that THC metabolizes rapidly and delay would result in loss of evidence. However, the U.S. Supreme Court's decision in Missouri v. McNeely (2013) had already held that the natural dissipation of alcohol in blood does not automatically create exigency, requiring case-by-case analysis. Several state courts have extended McNeely to cannabis cases, requiring warrants absent true exigency. Commonwealth v. Gerhardt (Pennsylvania Supreme Court, 2021) addressed whether the state's zero-tolerance law violated due process by criminalizing non-impairing levels of metabolites. The court held that the statute was rationally related to highway safety and that the legislature could reasonably conclude that any presence of cannabis metabolites indicated recent use and potential impairment. The dissent argued that criminalizing the presence of inactive metabolites that can persist for weeks bore no rational relationship to actual impairment. People v. Feezel (Colorado Supreme Court, 2019) established that the 5 ng/mL per se limit creates a "permissible inference" of impairment but not a conclusive presumption, allowing defendants to present evidence that they were not actually impaired despite exceeding the limit. This ruling has been influential in other per se states.

Implied Consent Laws and Chemical Testing

All 50 states have implied consent laws providing that drivers automatically consent to chemical testing when lawfully arrested for DUI. Refusal typically results in automatic license suspension and can be used as evidence of consciousness of guilt. However, cannabis testing presents unique challenges. Blood testing is considered the gold standard for THC measurement but requires medical personnel, laboratory analysis, and 2-4 weeks for results. Oral fluid testing provides faster results but measures different compounds and has not been validated for impairment correlation. Urine testing detects inactive metabolites (THC-COOH) that indicate past use but not current impairment, making it unsuitable for DUI enforcement. Several states have adopted "electronic warrant" systems allowing officers to obtain judicial authorization for blood draws via tablet or smartphone within 15-30 minutes, addressing Fourth Amendment concerns while preserving evidence.

State-by-State Breakdown of Major Legal Markets

California

California uses an impairment-based standard under Vehicle Code Section 23152(f), which prohibits driving "under the influence of any drug." The state does not have a per se THC limit. Prosecutors must prove impairment through officer observations, field sobriety tests, and expert testimony. The California Highway Patrol has trained approximately 1,200 Drug Recognition Experts statewide. In 2024, California courts processed 8,347 cannabis DUI cases, with a conviction rate of 64%—lower than the 89% conviction rate for alcohol DUI. The state conducted a pilot program testing the SoToxa oral fluid device in Los Angeles and Sacramento counties from 2022-2024, but the California Office of Traffic Safety declined to recommend statewide adoption due to accuracy concerns.

Colorado

Colorado established a 5 ng/mL per se limit in 2013 under C.R.S. 42-4-1301(6)(a)(IV). The limit creates a "permissible inference" of impairment that defendants can rebut. Colorado State Patrol data shows that of 4,892 cannabis DUI arrests in 2024, only 2,156 (44%) resulted in blood tests showing THC levels above 5 ng/mL. Of those tested below the limit, 67% were still convicted based on officer testimony and DRE evaluations. The Colorado Department of Transportation has spent $9.2 million on the "Drive High, Get a DUI" public awareness campaign since 2015. Crash data shows that THC-positive drivers increased from 10% of fatal crashes in 2013 to 18% in 2024, though 71% of THC-positive drivers also tested positive for alcohol.

Washington

Washington adopted a 5 ng/mL per se limit in 2012 under RCW 46.61.502(1)(b). The state also prohibits driving with THC concentrations of 1.0 ng/mL or higher for drivers under 21. Washington State Patrol reported 3,248 cannabis DUI arrests in 2024, with a conviction rate of 71%. The state has invested heavily in DRE training, with 412 certified officers as of 2025. A 2023 Washington Traffic Safety Commission study found that cannabis-involved crashes increased 28% from 2012 to 2022, but researchers noted that increased testing and reporting may account for much of the rise rather than actual increases in impaired driving.

Michigan

Michigan initially adopted a zero-tolerance standard for THC in 2003, but amended the law in 2016 to exempt registered medical marijuana patients. Under MCL 257.625(8), prosecutors must prove that a medical marijuana patient drove with "any amount of marijuana" in their system "and the person was operating the vehicle in a manner that demonstrated impairment." For non-patients, any detectable THC remains illegal. Michigan State Police processed 2,947 cannabis DUI cases in 2024. The state's oral fluid testing pilot program, suspended in 2019, has not resumed due to budget constraints and unresolved accuracy questions.

Massachusetts

Massachusetts uses an impairment-based standard under M.G.L. c. 90 § 24(1)(a)(1), requiring proof that the defendant's ability to operate a vehicle safely was diminished by cannabis use. The state does not have a per se limit. Massachusetts State Police have trained 187 Drug Recognition Experts. In 2024, Massachusetts courts handled 1,834 cannabis DUI cases, with a conviction rate of 58%. Defense attorneys have successfully challenged DRE testimony in several high-profile cases, arguing that the 12-step protocol was not designed for cannabis and lacks scientific validation for THC-specific impairment.

Illinois

Illinois established a dual standard in 2019 under 625 ILCS 5/11-501(a)(6). The law creates a per se violation for THC levels of 5 ng/mL or higher in blood or 10 ng/mL in oral fluid, while also prohibiting driving "under the influence of cannabis." Medical cannabis patients are exempt from the per se limits but can still be prosecuted for impairment. Illinois State Police reported 4,127 cannabis DUI arrests in 2024, with 62% involving THC levels above the per se limit. The state has equipped 450 officers with oral fluid testing devices, primarily the SoToxa system.

New York

New York legalized recreational cannabis in 2021 but does not have a per se THC limit. Under Vehicle and Traffic Law § 1192(4), prosecutors must prove impairment by drugs. The state has invested $8.5 million in training 650 Drug Recognition Experts since 2021. New York State Police processed 2,156 cannabis DUI cases in 2024. The state conducted a feasibility study of oral fluid testing in 2023 but has not implemented roadside screening due to concerns about accuracy and civil liberties. The New York Civil Liberties Union has opposed oral fluid testing without stronger validation studies and clearer protocols for protecting medical cannabis patients.

Market and Business Implications

Cannabis impaired driving concerns directly impact insurance markets, employment policies, multi-state operator liability, and the pace of legalization in conservative states. Insurance companies have responded to legalization by raising auto insurance premiums in legal states. A 2025 analysis by the Insurance Institute for Highway Safety found that premiums in Colorado increased 7.3% more than in neighboring states between 2014 and 2024, after controlling for other factors. Insurers cite increased crash frequency and severity, though they acknowledge difficulty isolating cannabis as a causal factor. Some insurers have introduced "cannabis-free driver" discounts of 5-10% for policyholders who agree to random testing, though uptake has been minimal due to privacy concerns. Employment policies in safety-sensitive industries remain in flux. The Federal Motor Carrier Safety Administration (FMCSA) requires commercial drivers to submit to drug testing and prohibits any cannabis use, regardless of state law. Under 49 CFR § 382.213, a positive test for THC results in immediate disqualification. This creates a conflict in legal states where drivers may consume cannabis off-duty but face federal penalties for metabolites detected days later. The Owner-Operator Independent Drivers Association has called for federal research into impairment-based testing to replace the current zero-tolerance approach, but FMCSA has not indicated any policy changes. Multi-state operators (MSOs) in the cannabis industry face unique liability exposure. Delivery drivers, budtenders who drive company vehicles, and executives traveling between facilities create potential negligence claims if involved in crashes. Several MSOs have implemented policies prohibiting any cannabis consumption during work hours and requiring 12-hour abstention before driving company vehicles, even in states where such policies exceed legal requirements. Curaleaf, Trulieve, and Green Thumb Industries have all faced civil lawsuits alleging negligent hiring or supervision after employees were involved in crashes, though most cases settled confidentially. The impaired driving issue has become a key talking point for legalization opponents. In the 2024 Florida recreational cannabis ballot initiative (which failed with 57% support, short of the required 60%), the "Vote No on 3" campaign emphasized impaired driving concerns in television advertisements. Similarly, opponents of legalization efforts in Kentucky, Kansas, and South Carolina have cited rising crash rates in Colorado and Washington as evidence that legalization threatens public safety. Proponents counter that crash rates have increased nationwide due to distracted driving and that THC-positive crash involvement does not prove causation.

What Experts Say About Impairment Testing and Policy

The scientific community remains divided on whether reliable roadside impairment testing for cannabis is achievable with current technology. Dr. Marilyn Huestis, a former chief of chemistry and drug metabolism at the National Institute on Drug Abuse, has stated that "THC concentrations in blood do not correlate well with impairment, especially in chronic users who develop tolerance." According to Dr. Huestis, occasional users may show significant impairment at 5 ng/mL, while daily users may function normally at 20 ng/mL or higher. She advocates for performance-based testing using cognitive and psychomotor assessments rather than relying solely on THC concentrations. Dr. Thomas Marcotte, the lead researcher on the May 2026 University of California San Diego study, said the findings on edible cannabis and alcohol combinations "should prompt immediate reconsideration of current legal frameworks that treat all cannabis consumption identically." According to Dr. Marcotte, edibles produce a different impairment profile than inhaled cannabis, with delayed onset, longer duration, and potentially greater synergistic effects with alcohol. He recommends that states consider separate legal standards for edibles and develop public education campaigns warning against combining cannabis with alcohol. The National Safety Council, a nonprofit focused on injury prevention, released a 2024 position statement calling for states to adopt a "zero tolerance" approach for drivers under 21 and a 5 ng/mL per se limit for adults, while also investing in DRE training and oral fluid testing technology. According to the organization's president, Lorraine Martin, "we cannot let the perfect be the enemy of the good—while no test is perfect, we have sufficient evidence that cannabis impairs driving and we need enforceable standards to protect the public." The American Civil Liberties Union has taken the opposite position. In a 2023 report titled "Driving While Black and High," the ACLU presented data showing that Black drivers in Colorado are 2.7 times more likely to be arrested for cannabis DUI than white drivers, despite similar usage rates. According to ACLU senior policy analyst Ezekiel Edwards, "per se limits and subjective officer evaluations create opportunities for discriminatory enforcement and criminalize legal behavior by medical patients and responsible consumers." Dr. Igor Grant, director of the Center for Medicinal Cannabis Research at UC San Diego, has emphasized the need for more naturalistic driving studies. According to Dr. Grant, "most research uses driving simulators or closed courses, which may not capture real-world driving behavior and decision-making." He advocates for instrumented vehicle studies where participants drive on public roads under controlled conditions, though he acknowledges the ethical and legal challenges of such research.

What's Next: Policy Developments and Research Priorities

The next 18 months will see critical decisions on federal rescheduling, state legislative reforms, and the potential approval of new testing technologies. The DEA's ongoing review of cannabis scheduling, initiated by President Biden's October 2022 directive, could result in reclassification to Schedule III by late 2026. Rescheduling would not directly change impaired driving laws, which are state-level matters, but would remove federal research barriers and potentially allow the National Institutes of Health (NIH) to fund large-scale studies on impairment testing. The National Highway Traffic Safety Administration has indicated that it would use any additional research funding to conduct a multi-state naturalistic driving study tracking 5,000 participants over three years. Several states have active legislation addressing cannabis impaired driving. Ohio introduced House Bill 447 in January 2026, which would lower the per se limit from 2 ng/mL to 1 ng/mL and establish a separate limit of 15 ng/mL for edible-derived THC. The bill faces opposition from patient advocates and is currently in committee. New Jersey is considering Assembly Bill 3891, which would establish the state's first per se limit of 5 ng/mL after operating without one since legalization in 2021. Pennsylvania lawmakers introduced Senate Bill 832 to eliminate the zero-tolerance standard for medical patients and replace it with an impairment-based standard. Technology development continues, with three companies—Hound Labs, Cannabix Technologies, and SannTek Labs—working on breath-based THC detection devices. Hound Labs' Hound Cannabis Breathalyzer received preliminary approval from the California Department of Justice in March 2026 for field testing. The device measures THC in breath within a two-hour detection window, which the company argues correlates better with impairment than blood testing. However, independent validation studies have not yet been published in peer-reviewed journals. The National Conference of State Legislatures has scheduled a summit on cannabis impaired driving for September 2026 in Denver, bringing together lawmakers, researchers, law enforcement, and industry representatives. The agenda includes sessions on oral fluid testing validation, DRE program effectiveness, and model legislation for states considering legalization. Public education campaigns are expanding. The Ad Council launched a national "Cannabis Conversations" campaign in February 2026, focusing on the risks of combining cannabis with alcohol and the delayed impairment from edibles. The $12 million campaign includes television, digital, and social media advertising in 15 states. Early tracking data shows a 23% increase in awareness that combining cannabis and alcohol is more dangerous than either substance alone.

Further Reading and Primary Sources

• National Highway Traffic Safety Administration, "Drug-Impaired Driving: A Guide for States" (2024) - https://www.nhtsa.gov/document/drug-impaired-driving-guide-states
• American Automobile Association, "An Evaluation of Data from Recent Studies to Determine the Relationship Between Blood THC Concentration and Impairment" (2016) - https://www.aaafoundation.org/impaired-driving-cannabis-thc
• National Institute on Drug Abuse, "Cannabis (Marijuana) Research Report: Does marijuana use affect driving?" - https://nida.nih.gov/publications/research-reports/marijuana/does-marijuana-use-affect-driving
• Colorado Department of Transportation, "Cannabis and Driving" data dashboard - https://www.codot.gov/safety/alcohol-and-impaired-driving/druggeddriving
• Insurance Institute for Highway Safety, "Marijuana legalization and traffic crashes" (2025) - https://www.iihs.org/topics/alcohol-and-drugs/marijuana
• Marcotte et al., "Combined Effects of THC Edibles and Alcohol on Driving Performance" Traffic Injury Prevention (2026) - https://www.tandfonline.com/toc/gcpi20/current
• ACLU, "Driving While Black and High: Racial Disparities in Cannabis DUI Enforcement" (2023) - https://www.aclu.org/report/driving-while-black-and-high
• National Safety Council, "Impairment Detection and Roadside Testing" position statement - https://www.nsc.org/road/safety-topics/impaired-driving
• Drug Recognition Expert International Association - https://www.theiacp.org/drug-recognition-expert-dre-program
• Substance Abuse and Mental Health Services Administration, National Survey on Drug Use and Health (2025) - https://www.samhsa.gov/data/release/2025-national-survey-drug-use-and-health-nsduh-releases